Patents by Inventor Jean-Louis Junien

Jean-Louis Junien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11999758
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 4, 2024
    Assignee: INVENTIVA
    Inventors: Martine Barth, Sylvie Contal, Jean-Louis Junien, Christine Massardier, Christian Montalbetti, Anne Soude
  • Patent number: 11504380
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 22, 2022
    Assignee: INVENTIVA
    Inventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
  • Publication number: 20210323982
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.
    Type: Application
    Filed: October 2, 2019
    Publication date: October 21, 2021
    Inventors: Martine BARTH, Sylvie CONTAL, Jean-Louis JUNIEN, Christine MASSARDIER, Christian MONTALBETTI, Anne SOUDE
  • Publication number: 20210137937
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 13, 2021
    Inventors: Guillaume WETTSTEIN, Pierre BROQUA, Jean-Louis JUNIEN
  • Publication number: 20200115353
    Abstract: The invention relates to compounds of formula: wherein R1 to R7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
    Type: Application
    Filed: April 6, 2018
    Publication date: April 16, 2020
    Inventors: Martine BARTH, Slyvie CONTAL, Jean-Louis JUNIEN, Christine MASSARDIER, Christian MONTALBETTI, Anne SOUDE
  • Patent number: 10383858
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: August 20, 2019
    Assignee: INVENTIVA
    Inventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
  • Publication number: 20180333396
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 22, 2018
    Inventors: Irena KONSTANTINOVA, Jean-Michel LUCCARINI, Jean-Louis JUNIEN, Pierre BROQUA
  • Patent number: 10092540
    Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 9, 2018
    Assignee: INVENTIVA
    Inventors: Philippe Masson, Jean-Louis Junien, Mireille Tallandier
  • Patent number: 10052311
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 21, 2018
    Assignee: INVENTIVA
    Inventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
  • Publication number: 20170189383
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Application
    Filed: June 12, 2015
    Publication date: July 6, 2017
    Inventors: Irena KONSTANTINOVA, Jean-Michel LUCCARINI, Jean-Louis JUNIEN, Pierre BROQUA
  • Publication number: 20170189375
    Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.
    Type: Application
    Filed: January 31, 2017
    Publication date: July 6, 2017
    Inventors: Philippe MASSON, Jean-Louis JUNIEN
  • Patent number: 9561246
    Abstract: The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: February 7, 2017
    Assignee: Inventiva
    Inventors: Philippe Masson, Jean-Louis Junien
  • Patent number: 8030335
    Abstract: The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Laboratoires Fournier S.A.
    Inventors: Bernadette Husson, Pierre Broqua, Jean-Louis Junien
  • Publication number: 20100297761
    Abstract: A method of increasing the ex vivo viability of pancreatic islet cells comprising contacting the islet cells with a liver X receptor (LXR) agonist, particularly an LXRalpha agonist. Examples of especially useful LXR agonists include GW3965 and T0901317.
    Type: Application
    Filed: May 26, 2010
    Publication date: November 25, 2010
    Applicant: LABORATOIRE FOURNIER S.A. French Limited Company
    Inventors: Bernadette HUSSON, Pierre Broqua, Jean-Louis Junien
  • Publication number: 20100144874
    Abstract: The present invention relates to the combined use of a PPAR? agonist and metformin for decreasing serum triglycerides.
    Type: Application
    Filed: February 12, 2010
    Publication date: June 10, 2010
    Applicant: Fournier Laboratories Ireland Limited
    Inventors: Jean-Louis Junien, Alan Edgar, Evelyne Chaput
  • Publication number: 20100029575
    Abstract: Certain peptides which exhibit high selectivity for the kappa opioid receptor (KOR) versus the mu opioid receptor and little or no CYP3A4 inhibitory activity including tetrapeptides of four D-isomer amino acid residues having a C-terminus which is an N-oxide-substituted amide such, as H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl-N-oxide.
    Type: Application
    Filed: May 25, 2007
    Publication date: February 4, 2010
    Inventors: Jean-Louis Junien, Pierre J.M. Riviere, Claudio D. Schteingart, Javier Sueiras Diaz, Jerzy A. Trojnar, Todd W. Vanderah, Michael E. Lewis
  • Publication number: 20090118306
    Abstract: The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.
    Type: Application
    Filed: May 10, 2006
    Publication date: May 7, 2009
    Applicant: LABORATOIRE FOURNIER S.A. French Limited Compay
    Inventors: Bernadette Husson, Pierre Broqua, Jean-Louis Junien
  • Publication number: 20090099238
    Abstract: The present invention relates to the use of a ppar? agonist to treat patients suffering from weight gain associated with a ppar? agonist treatment.
    Type: Application
    Filed: October 10, 2008
    Publication date: April 16, 2009
    Inventors: Jean-Louis Junien, Alan Edgar, Evelyne Chaput
  • Publication number: 20090062240
    Abstract: The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as well as asthma or related airway or resp
    Type: Application
    Filed: July 25, 2005
    Publication date: March 5, 2009
    Applicant: Fournier Laboratories Ireland Limited
    Inventors: Alan Edgar, Jean-Louis Junien, Michael Wilkins
  • Publication number: 20070060532
    Abstract: The present invention relates to anti-obesity pharmaceutical compositions comprising orlistat and metformin and to the use of combinations of metformin and orlistat to treat patients suffering from obesity.
    Type: Application
    Filed: September 12, 2006
    Publication date: March 15, 2007
    Applicant: Fournier Laboratories Ireland Limited
    Inventors: Jean-Louis Junien, Alan Edgar